Izokibep

依泽吉贝普

Report date: 2026/04/07 20:00:20

Base Information

Drug NameIzokibep
Drug Alias NameAFB-035ABY-035IMG-020IMG020ABY-035/AFO2 +[6
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisPsoriasisUveitis +[6
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[17
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAffibody Ab
China Registration ClassN/A

Develop Information

Inactive CompaniesInmagene LLC
Active IndicationsPlaque psoriasisUveitisArthritis, Psoriatic
Inactive IndicationsPsoriasisSpondylitis, AnkylosingHidradenitis Suppurativa

Other Information

ATC CodeN/A
Related LinksN/A